Ruolo della farmacologia clinica nel monitoraggio della terapia in soggetti con infezione da HIV

Translated title of the contribution: Role of clinical pharmacology in monitoring AIDS therapies

Paola Villani, Laura Cocchi, Roberto Giacchino, Elena Seminari, Mario B. Regazzi, Renato Maserati

Research output: Contribution to journalArticle

Abstract

The number of subjects with HIV infection or full-blown Acquired Immunodeficiency Syndrome (AIDS) is increasing throughout the world and the range of related opportunistic conditions (infections, neoplasms or degenerative disorders) is also increasing. Consequently, AIDS patients are likely to be prescribed a greater number of different drugs. HIV infection is a progressive phenomenon, characterized by inevitable and often irreversible changes which may influence drug disposition, enhancing the risk of toxic adverse effects and drug interactions. One of the stages for the development of new agents and the establishment of an effective therapy is to conduct pharmacokinetic studies. Even though such studies are difficult to realize in AIDS subjects, the knowledge of altered pharmacokinetics of a drug in disease states offers an unique approach for improving and perhaps optimizing the therapeutic management. The purpose of this article is to review our current understanding of how HIV infection influences the various processes of drug disposition (i.e. absorption, distribution, metabolism and excretion).

Original languageItalian
Pages (from-to)279-293
Number of pages15
JournalClinica Terapeutica
Volume147
Issue number6
Publication statusPublished - 1996

Fingerprint

Clinical Pharmacology
Acquired Immunodeficiency Syndrome
HIV Infections
Pharmaceutical Preparations
Pharmacokinetics
Poisons
Opportunistic Infections
Therapeutics
Drug Interactions
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ruolo della farmacologia clinica nel monitoraggio della terapia in soggetti con infezione da HIV. / Villani, Paola; Cocchi, Laura; Giacchino, Roberto; Seminari, Elena; Regazzi, Mario B.; Maserati, Renato.

In: Clinica Terapeutica, Vol. 147, No. 6, 1996, p. 279-293.

Research output: Contribution to journalArticle

@article{5bf908bbd12b4d038b1650238093bebb,
title = "Ruolo della farmacologia clinica nel monitoraggio della terapia in soggetti con infezione da HIV",
abstract = "The number of subjects with HIV infection or full-blown Acquired Immunodeficiency Syndrome (AIDS) is increasing throughout the world and the range of related opportunistic conditions (infections, neoplasms or degenerative disorders) is also increasing. Consequently, AIDS patients are likely to be prescribed a greater number of different drugs. HIV infection is a progressive phenomenon, characterized by inevitable and often irreversible changes which may influence drug disposition, enhancing the risk of toxic adverse effects and drug interactions. One of the stages for the development of new agents and the establishment of an effective therapy is to conduct pharmacokinetic studies. Even though such studies are difficult to realize in AIDS subjects, the knowledge of altered pharmacokinetics of a drug in disease states offers an unique approach for improving and perhaps optimizing the therapeutic management. The purpose of this article is to review our current understanding of how HIV infection influences the various processes of drug disposition (i.e. absorption, distribution, metabolism and excretion).",
keywords = "drugs biodisponibility, HIV infection",
author = "Paola Villani and Laura Cocchi and Roberto Giacchino and Elena Seminari and Regazzi, {Mario B.} and Renato Maserati",
year = "1996",
language = "Italian",
volume = "147",
pages = "279--293",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "6",

}

TY - JOUR

T1 - Ruolo della farmacologia clinica nel monitoraggio della terapia in soggetti con infezione da HIV

AU - Villani, Paola

AU - Cocchi, Laura

AU - Giacchino, Roberto

AU - Seminari, Elena

AU - Regazzi, Mario B.

AU - Maserati, Renato

PY - 1996

Y1 - 1996

N2 - The number of subjects with HIV infection or full-blown Acquired Immunodeficiency Syndrome (AIDS) is increasing throughout the world and the range of related opportunistic conditions (infections, neoplasms or degenerative disorders) is also increasing. Consequently, AIDS patients are likely to be prescribed a greater number of different drugs. HIV infection is a progressive phenomenon, characterized by inevitable and often irreversible changes which may influence drug disposition, enhancing the risk of toxic adverse effects and drug interactions. One of the stages for the development of new agents and the establishment of an effective therapy is to conduct pharmacokinetic studies. Even though such studies are difficult to realize in AIDS subjects, the knowledge of altered pharmacokinetics of a drug in disease states offers an unique approach for improving and perhaps optimizing the therapeutic management. The purpose of this article is to review our current understanding of how HIV infection influences the various processes of drug disposition (i.e. absorption, distribution, metabolism and excretion).

AB - The number of subjects with HIV infection or full-blown Acquired Immunodeficiency Syndrome (AIDS) is increasing throughout the world and the range of related opportunistic conditions (infections, neoplasms or degenerative disorders) is also increasing. Consequently, AIDS patients are likely to be prescribed a greater number of different drugs. HIV infection is a progressive phenomenon, characterized by inevitable and often irreversible changes which may influence drug disposition, enhancing the risk of toxic adverse effects and drug interactions. One of the stages for the development of new agents and the establishment of an effective therapy is to conduct pharmacokinetic studies. Even though such studies are difficult to realize in AIDS subjects, the knowledge of altered pharmacokinetics of a drug in disease states offers an unique approach for improving and perhaps optimizing the therapeutic management. The purpose of this article is to review our current understanding of how HIV infection influences the various processes of drug disposition (i.e. absorption, distribution, metabolism and excretion).

KW - drugs biodisponibility

KW - HIV infection

UR - http://www.scopus.com/inward/record.url?scp=0029961977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029961977&partnerID=8YFLogxK

M3 - Articolo

C2 - 8925637

AN - SCOPUS:0029961977

VL - 147

SP - 279

EP - 293

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 6

ER -